30 Apr 2013 Posted in News Release By Press Office
"Whilst we cannot comment on individual cases, there are clearly a number complex issues that need to be considered when disclosing clinical trial information. Firstly, it is essential that patient confidentiality is not compromised. Secondly, it is important commercially sensitive information is not published which may undermine companies’ intellectual property and in turn their ability to research and develop new medicines. We are currently in discussion with a wide range of stakeholders, to develop practical solutions to these issues."
ABPI Press Office
Tel: +44 (0) 20 7747 1441 or +44 (0) 20 7747 1410
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.